Jorge Labrador
Overview
Explore the profile of Jorge Labrador including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
72
Citations
638
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Labrador J, Martinez-Cuadron D, Boluda B, Serrano J, Gil C, Perez-Simon J, et al.
Cancer
. 2024 Jun;
130(20):3436-3451.
PMID: 38896056
Background: There are no studies assessing the evolution and patterns of genetic studies performed at diagnosis in acute myeloid leukemia (AML) patients. Such studies could help to identify potential gaps...
12.
Lahmer T, Salmanton-Garcia J, Marchesi F, El-Ashwah S, Nucci M, Besson C, et al.
Infection
. 2024 May;
52(3):1191-1194.
PMID: 38771466
No abstract available.
13.
Aiello T, Salmanton-Garcia J, Marchesi F, Weinbergerova B, Glenthoj A, van Praet J, et al.
Haematologica
. 2024 Apr;
109(8):2693-2700.
PMID: 38572549
No abstract available.
14.
Salmanton-Garcia J, Marchesi F, Farina F, Weinbergerova B, Itri F, Davila-Valls J, et al.
EClinicalMedicine
. 2024 Mar;
71:102553.
PMID: 38533127
Background: The COVID-19 pandemic heightened risks for individuals with hematological malignancies due to compromised immune systems, leading to more severe outcomes and increased mortality. While interventions like vaccines, targeted antivirals,...
15.
Hontecillas-Prieto L, Garcia-Dominguez D, Palazon-Carrion N, Garcia-Sancho A, Nogales-Fernandez E, Jimenez-Cortegana C, et al.
Front Immunol
. 2024 Mar;
15:1293931.
PMID: 38469299
Background: Diffuse large B cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma worldwide. DLBCL is an aggressive disease that can be cured with upfront standard chemoimmunotherapy schedules. However, in...
16.
Lahmer T, Salmanton-Garcia J, Marchesi F, El-Ashwah S, Nucci M, Besson C, et al.
Infection
. 2024 Feb;
52(3):1125-1141.
PMID: 38388854
No abstract available.
17.
Sobas M, Knopinska-Posluszny W, Piatkowska-Jakubas B, Garcia-Alvarez F, Diez M, Caballero M, et al.
Ann Hematol
. 2023 Dec;
103(2):451-461.
PMID: 38110588
The most important challenges in acute promyelocytic leukemia (APL) is preventing early death and reducing long-term events, such as second neoplasms (s-NPLs). We performed a retrospective analysis of 2670 unselected...
18.
Musto P, Salmanton-Garcia J, Sgherza N, Bergantim R, Farina F, Glenthoj A, et al.
Hematol Oncol
. 2023 Dec;
42(1):e3240.
PMID: 38050405
Patients affected by multiple myeloma (MM) have an increased risk of severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) infection and subsequent coronavirus (20)19 disease (COVID-19)-related death. The changing epidemiological...
19.
Chatzikonstantinou T, Scarfo L, Karakatsoulis G, Minga E, Chamou D, Iacoboni G, et al.
EClinicalMedicine
. 2023 Nov;
65:102307.
PMID: 38033506
Background: Patients with chronic lymphocytic leukemia (CLL) have a higher risk of developing other malignancies (OMs) compared to the general population. However, the impact of CLL-related risk factors and CLL-directed...
20.
El-Ashwah S, Salmanton-Garcia J, Bilgin Y, Itri F, Zak P, Weinbergerova B, et al.
Leuk Lymphoma
. 2023 Nov;
65(2):199-208.
PMID: 37966980
Since the beginning of the COVID-19 pandemic, there has been an overall improvement in patient mortality. However, haematological malignancy patients continue to experience significant impacts from COVID-19, including high rates...